Skip to main content
Retour
Watch Compare

Atara Biotherapeutics, Inc.

Qualité des données : 100%
ATRA
Nasdaq Manufacturing Chemicals
4,70 €
▼ 0,32 € (-6,29%)
Cap. Boursière: 38,40 M
Prix
4,70 €
Cap. Boursière
38,40 M
Fourchette du Jour
4,44 € — 5,04 €
Fourchette 52 Semaines
3,92 € — 19,15 €
Volume
116 150
Ouverture 5,03 €
Moyenne 50J / 200J
5,08 €
7,65% below
Moyenne 50J / 200J
10,71 €
56,17% below

Quick Summary

Points Clés

Net margin of 27,07% shows strong profitability
Negative free cash flow of -50,94 M
P/E of 1,17 — trading at a low valuation
Capital efficient — spends only 0,00% of revenue on capex
ROIC of 208,01% — excellent capital efficiency

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-6,33%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC208,01%
Net Margin27,07%
Op. Margin29,69%

Sécurité

Debt / Equity
N/A
Current Ratio1,02
Interest Coverage9,46

Valorisation

PE (TTM)
1,17
Au-dessus de la moyenne du secteur (-1,98)
P/B RatioN/A
EV/EBITDA0,86
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (44 pairs)
Métrique Action Médiane du Secteur
P/E 1,2 -2,0
P/B — 5,1
ROE % — -51,0
Net Margin % 27,1 -150,2
Rev Growth 5Y % — 9,3
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -6,33% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 120,77 M Net Income (TTM) 32,69 M
ROE N/A ROA 97,48%
Gross Margin N/A Operating Margin 29,69%
Net Margin 27,07% Free Cash Flow (TTM) -50,94 M
ROIC 208,01% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,02
Interest Coverage 9,46 Asset Turnover 3,60
Working Capital 375 000 Tangible Book Value -36,63 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 1,17 Forward P/E N/A
P/B Ratio N/A P/S Ratio 0,32
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 0,86 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -132,67%
Market Cap 38,40 M Enterprise Value 32,65 M
Per Share
EPS (Diluted TTM) 2,57 Revenue / Share 14,77
FCF / Share -6,23 OCF / Share -6,23
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,00% FCF Conversion -155,84%
SBC-Adj. FCF -65,60 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 120,77 M 128,94 M — — —
Net Income 32,69 M -85,40 M -276,13 M -228,30 M -340,14 M
EPS (Diluted) 2,57 -11,41 -2,61 -2,24 —
Gross Profit — — — — —
Operating Income 35,86 M -83,44 M -276,01 M -280,51 M -340,46 M
EBITDA — — — — —
R&D Expenses 37,45 M 151,48 M 224,79 M 272,53 M 282,00 M
SG&A Expenses — — — — —
D&A 2,12 M 5,05 M 4,83 M 5,65 M 9,35 M
Interest Expense 3,79 M 4,62 M 5,29 M — —
Income Tax 31 000,0 -12 000,0 15 000,0 12 000,0 46 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 20,24 M 109,10 M 165,50 M 376,42 M 468,13 M
Total Liabilities 58,74 M 206,38 M 264,74 M 249,78 M 188,51 M
Shareholders' Equity -38,50 M -97,28 M -99,23 M 126,64 M 279,61 M
Total Debt — — — — —
Cash & Equivalents 8,48 M 25,03 M 25,84 M 92,94 M 106,08 M
Current Assets 12,21 M 64,89 M 101,87 M 295,08 M 384,62 M
Current Liabilities 14,92 M 134,57 M 142,23 M 78,92 M 105,79 M